{"id":"W4389329605","doi":"10.1182/bloodadvances.2023011721","title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Ludwig Center at Harvard; Sierra Oncology; Astellas Pharma; U.S. Department of Defense; Gilead Sciences; Genentech; Bristol-Myers Squibb; AstraZeneca; Servier; Pfizer","keywords":"Azacitidine; Medicine; Venetoclax; Internal medicine; Hypomethylating agent; Myeloid leukemia; Adverse effect; Interleukin-3 receptor; Minimal residual disease; Leukemia; Decitabine; Myelodysplastic syndromes; Oncology; Gastroenterology; Immunology; Chronic lymphocytic leukemia; Bone marrow; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004760242,0.0002560906,0.0007301341,0.0006826586,0.00004087305,0.00001530707,0.0001935367,0.0001053565,0.0000298084],"category_scores_gemma":[0.0001533842,0.0001684354,0.00004358996,0.002251029,0.0002340408,0.0003310615,0.00005596319,0.000420936,0.00001416923],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004579285,"about_ca_system_score_gemma":0.001495149,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001869577,"about_ca_topic_score_gemma":0.001021137,"domain_scores_codex":[0.9977511,0.00009391682,0.0004833763,0.0004522672,0.0007069368,0.0005123683],"domain_scores_gemma":[0.9989652,0.0002028558,0.000188161,0.0003670257,0.0001430402,0.000133687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7585801,0.008642949,0.1031679,0.001468147,0.0008634435,0.007077766,0.002616298,0.001244318,0.05133743,0.000674615,0.0005117402,0.06381533],"study_design_scores_gemma":[0.8776702,0.03514524,0.006962709,0.001403342,0.0003343239,0.0002682973,0.001267313,0.003941738,0.06864189,0.0002273263,0.00360432,0.0005332763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964942,0.0001911866,0.0000698466,0.0003636389,0.00005560081,0.001903911,0.00002569795,0.0000969787,0.0007988967],"genre_scores_gemma":[0.9950117,0.0008545809,0.002213228,0.00006033625,0.00009998467,0.0003338864,0.00013404,0.00005452256,0.001237701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1190901,"threshold_uncertainty_score":0.6868595,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02240965027802033,"score_gpt":0.3371219432877385,"score_spread":0.3147122930097182,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}